# NeoPhore

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neophore

- Industry: Biotechnology
- Headquarters: Cheshire, UK
- Website: www.neophore.com
- Total disclosed funding: $43M
- Latest round: Series B (Jan 5, 2024)
- Investors on record: 7

## About

Based in Cheshire, UK, and founded in 2017, NeoPhore Ltd. operates as a biotechnology company that develops small-molecule therapies. The company was founded by Alberto Bardelli. In April 2024, NeoPhore Ltd. raised GBP 5.02 million of Series B funding from Bristol-Myers Squibb Company. The Series B round of financing values NeoPhore Ltd. at GBP 56.10 million post-money. As of 2024, the company is led by its CEO, Matthew Baker.

NeoPhore offers novel small-molecule immuno-oncology therapeutics. The company develops small-molecule drugs to treat cancer.

The company plans to use the funds raised in April 2024 to further research its deoxyribonucleic acid mismatch repair pathway and accelerate the progression of its pre-clinical studies.

## Funding rounds

- Series B, Jan 5, 2024, $12M — Astellas Venture Management, Sixth Element Capital, 3B Future Health Fund, Neva, Claris Ventures, 2Invest, LIFTT
- Series B, Dec 8, 2022, $7.1M — Astellas Venture Management, Sixth Element Capital, 3B Future Health Fund, Claris Ventures, 2Invest
- Series B, Feb 16, 2021, $24M — Astellas Venture Management, Sixth Element Capital, 3B Future Health Fund, Claris Ventures, 2Invest

## Investors

- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B
- Sixth Element Capital (https://capitalatlas.ai/funds/sixth-element-capital) — Series B
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series B
- Claris Ventures (https://capitalatlas.ai/funds/claris-ventures) — Series B
- 2Invest — Series B
- Neva (https://capitalatlas.ai/funds/neva) — Series B
- LIFTT (https://capitalatlas.ai/funds/liftt) — Series B